Dupilumab is associated with reduced risk of acute upper respiratory infections in patients with atopic dermatitis compared with nontargeted immunosuppressants: A multicenter cohort study.

Competing Interests: Conflicts of interest Dr Kwatra is an advisory board member/consultant for AbbVie, Amgen, Arcutis Biotherapeutics, ASLAN Pharmaceuticals, Cara Therapeutics, Castle Biosciences, Celldex Therapeutics, Galderma, Genzada Pharmaceuticals, Incyte Corporation, Johnson & Johnson, LEO Pharma, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, and Sanofi and has served as an investigator for Galderma, Incyte, Pfizer, and Sanofi. Authors Ma, Bao, Ahmadi, and Zhang have no conflicts of interest to declare.